About Epizyme
Epizyme is a company based in Cambridge (United States) founded in 2007.. Epizyme has raised $51.5 million across 6 funding rounds from investors including Kleiner Perkins, Royalty Pharma and Celgene. Epizyme operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Epizyme, Inc.
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$5.8 M (USD)10.32as on Mar 31, 2023
-
Net Profit
$661.79 K (USD)-5.82as on Mar 31, 2023
-
EBITDA
$5.02 M (USD)9.54as on Mar 31, 2023
-
Total Equity Funding
$51.5 M (USD)
in 6 rounds
-
Latest Funding Round
$270 M (USD), Post-IPO
Nov 05, 2019
-
Investors
Kleiner Perkins
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Epizyme
Epizyme has successfully raised a total of $51.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $270 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $270.0M
-
First Round
First Round
(07 Oct 2009)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2019 | Amount | Post-IPO - Epizyme | Valuation |
investors |
|
| Feb, 2014 | Amount | Post-IPO - Epizyme | Valuation |
investors |
|
| Oct, 2011 | Amount | Series B - Epizyme | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Epizyme
Epizyme has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Founded Year | Domain | Location | |
|
Investment management services are provided to the life sciences industry.
|
Founded Year | Domain | Location | |
|
Research and patient support for blood cancers are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Epizyme
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Epizyme
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Epizyme Comparisons
Competitors of Epizyme
Epizyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Epizyme
Frequently Asked Questions about Epizyme
When was Epizyme founded?
Epizyme was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Where is Epizyme located?
Epizyme is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Epizyme a funded company?
Epizyme is a funded company, having raised a total of $51.5M across 6 funding rounds to date. The company's 1st funding round was a Series B of $4M, raised on Oct 07, 2009.
What is the annual revenue of Epizyme?
Annual revenue of Epizyme is $5.8M as on Mar 31, 2023.
What does Epizyme do?
Epizyme was founded in 2007 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where epigenetic therapies for cancer are developed. Lead candidates include TAZVERIK, approved for epithelioid sarcoma and follicular lymphoma, along with a protein arginine methyltransferase inhibitor targeted at solid tumors and blood cancers. Research and development efforts are centered on advancing these oncology solutions.
Who are the top competitors of Epizyme?
Epizyme's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Who are Epizyme's investors?
Epizyme has 11 investors. Key investors include Kleiner Perkins, Royalty Pharma, Celgene, GSK, and Leukemia & Lymphoma Society.